Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 11/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20481273 | 0.98 | HRH4 (0.43) | HRH4ITGAVITGB6MEN1KMT2A | |
| SCHEMBL276771 | 0.86 | ITGAV (0.38) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL22009147 | 0.84 | ITGAV (0.36) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20481147 | 0.83 | ITGAV (0.36) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL22893614 | 0.79 | ITGAV (0.38) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL2383101 | 0.78 | ITGAV (0.44) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL30335954 | 0.75 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL7007445 | 0.75 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20481212 | 0.74 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL13264843 | 0.73 | ITGAV (0.52) | ITGAVITGB6MEN1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-1315728-B1 | PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-07 | — | — | US | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| US-6743800-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND INHIBITORS OF CELL ADHESION; OSTEOPOROSIS, ANGIOGENESIS INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030171368-A1 | Pyrimidinonesulfamoylureas` | SEITZ WERNER (DE) | 2003-09-11 | — | — | US | disclosed |
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | HRH4 2703/4885ITGAV 3/4885ITGB6 1/4885 |
| US-20030171368-A1 | Pyrimidinonesulfamoylureas` | ITGB1, ITGA1, ITGAM | HRH4 1877/4885ITGAV 15/4885ITGB6 10/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | HRH4 2703/4885ITGAV 3/4885ITGB6 1/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | HRH4 3101/4885ITGAV 3/4885ITGB6 1/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | HRH4 2846/4885ITGAV 3/4885ITGB6 1/4885 |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | VCAM1, ADGRF1, ADGRE5 | HRH4 326/4885ITGAV 181/4885ITGB6 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.